Vivus has agreed to acquire all product rights for Pancreaze (pancrelipase) Delayed-Release Capsules in the US and Canada held by Janssen Pharmaceuticals, subject to certain closing conditions, including Hart-Scott-Rodino review.
C4X Discovery (C4XD) has entered into a joint research collaboration with e-Therapeutics (ETX) to identify novel mechanisms for the treatment of Parkinson’s Disease (PD).
NX Development (NXDC), a privately-held life sciences company, has announced a merger acquisition under which NXDC became a wholly-owned subsidiary of photonamic GmbH & Co. KG (PHN).
PhoreMost and NeoPhore are set to receiv £1m of funding to develop a novel small-molecule cancer immunotherapy program following award of a Biomedical Catalyst grant in a recent Innovate UK competition.
Corvidia Therapeutics has secured $60m in a Series B funding round to accelerate growth of its ongoing clinical programs, expand scientific and market access capabilities and explore new treatment areas.
Scientists from the University of Lincoln in the UK have created a new technique using nanotechnology which can make drugs more effective at reaching their target.
Tmunity Therapeutics, a biotherapeutics company focused on developing next-generation T cell immunotherapy, has raised new funding of $35m in a Series A investment from Kleiner Perkins and affiliates.
Ireland-based Shire has rejected a $63bn acquisition offer from Takeda Pharmaceutical, saying that it undervalues the company, its growth prospects and pipeline.
Sandoz, a division of Novartis, and Pear Therapeutics have agreed to jointly commercialize and continue development of novel prescription digital therapeutics designed to treat disease and improve clinical outcomes for patients.
Novartis said that it will invest more than $100m to advance research and development of new antimalarials over the next five years.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.